Intra-Articular Injection of Mitomycin C Prevents Progression of Immobilization-Induced Arthrogenic Contracture in the Remobilized Rat Knee

Akinori KANEGUCHI¹, Junya OZAWA¹, Kaoru YAMAOKA¹

¹Department of Rehabilitation, Faculty of Rehabilitation, Hiroshima International University, Higashi-Hiroshima, Hiroshima, Japan

Received February 21, 2019
Accepted October 17, 2019
Epub Ahead of Print December 19, 2019

Summary
This study tested whether cell cycle inhibitor mitomycin C (MMC) prevents arthrogenic contracture progression during remobilization by inhibiting fibroblast proliferation and fibrosis in the joint capsule. Rat knees were immobilized in a flexed position to generate flexion contracture. After three weeks, the fixation device was removed and rat knees were allowed to freely move for one week. Immediately after and three days after fixator removal, rats received intra-articular injections of MMC or saline. The passive extension range of motion (ROM) was measured before and after myotomy of the knee flexors to distinguish myogenic and arthrogenic contractures. In addition, both cellularity and fibrosis in the posterior joint capsule were assessed histologically. Joint immobilization significantly decreased ROMs both before and after myotomy compared with untreated controls. In saline-injected knees, remobilization increased ROM before myotomy, but further decreased that after myotomy compared with that of knees immediately after three weeks of immobilization. Histological analysis revealed that hypercellularity, mainly due to fibroblast proliferation, and fibrosis characterized by increases in collagen density and joint capsule thickness occurred after remobilization in saline-injected knees. Conversely, MMC injections were able to prevent the remobilization-enhanced reduction of ROM after myotomy by inhibiting both hypercellularity and joint capsule fibrosis. Our results suggest that joint capsule fibrosis accompanied by fibroblast proliferation is a potential cause of arthrogenic contracture progression during remobilization, and that inhibiting fibroblast proliferation may constitute an effective remedy.

Key words
Joint contracture • Immobilization • Fibroblast • Fibrosis • Mitomycin C

Corresponding author
J. Ozawa, Department of Rehabilitation, Faculty of Rehabilitation, Hiroshima International University, Kurose-Gakuendai 555-36, Higashi-Hiroshima, Hiroshima, 739-2695, Japan. Fax: +81-823-70-4542. E-mail: j-ozawa@hirokoku-u.ac.jp

Introduction
Joint immobilization is frequently used to treat orthopedic disorders such as bone fractures and ligamentous injuries, but often causes joint contracture (Chesworth and Vandervoort 1995, Moseley et al. 2005, Nightingale et al. 2007), which is characterized by a reduced passive range of motion (ROM) of the joint (Wong et al. 2015). As joint contractures can lead to various types of locomotive disabilities (Bot et al. 2012, De Smet 2007), management of this impairment is a critical issue in the field of orthopedics.

Because joint immobilization is a major cause of joint contracture, it is clinically accepted that joint movement during remobilization is effective in improving joint contracture. Passive joint movements such as stretching are frequently applied in this context. In animal studies, however, it remains controversial whether stretching has beneficial effects on immobilization-induced joint contracture (Kondo et al. 2012, Okita et al. 2001, Usuba et al. 2007). In humans,
a clinical study failed to show related benefits of passive stretching (Moseley et al. 2005), and recent reviews supported by high-quality evidence suggest that stretching does not have a clinically important role in joint contracture treatment (Harvey et al. 2017a, Harvey et al. 2017b). More reasonable and effective treatment approaches are therefore needed.

Formation and recovery processes of immobilization-induced joint contracture have been closely examined using animal models. The responsible structures have been broadly divided into myogenic and arthrogenic factors (Nagai et al. 2014, Trudel and Uhthoff 2000, Trudel et al. 2014). Trudel et al. demonstrated that a myogenic factor is mainly responsible for joint contracture in the early phases of immobilization (within two weeks) and is resolved by remobilization (Trudel et al. 2014). In contrast, arthrogenic factors largely contribute to severe joint contracture induced by prolonged (over four weeks) immobilization, and recovery by remobilization is not expected in these cases (Trudel et al. 2014). Arthrogenic contracture also further progresses during remobilization following short-term (within three weeks) immobilization (Kaneguchi and Ozawa 2017, Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2018b, Kaneguchi et al. 2019, Trudel et al. 2014). To avoid irreversible joint contracture, arthrogenic contracture should therefore be targeted.

Fibrosis in the joint components is believed to be the major factor contributing to development of arthrogenic contracture in injured (Fukui et al. 2000, Fukui et al. 2001, Gao et al. 2017, Li et al. 2013a) and immobilized joints (Sasabe et al. 2017). For example, administration of decorin, which suppresses bioactivity of cell adhesion, as well as fibrotic regulators, such as transforming growth factor-beta, can improve restricted joint motion in the rabbit intra-articular adhesion model (Fukui et al. 2001). However, several studies showed development of arthrogenic contracture without fibrosis in the periarticular connective tissue in spinal cord injury and immobilization models (Hagiwara et al. 2010, Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2018b, Kaneguchi et al. 2019, Moriyama et al. 2007). While it therefore remains controversial whether joint fibrosis is a major factor in arthrogenic contracture, development of fibrosis is observed in the joint capsule of remobilized joints together with progression of arthrogenic contracture (Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2018b, Kaneguchi et al. 2019). We previously showed that anti-inflammatory treatment using the steroidal drug dexamethasone can prevent remobilization-induced arthrogenic contracture progression by suppressing joint capsule fibrosis and fibroblast proliferation (Kaneguchi et al. 2018b). Other studies using intra-articular adhesion models also reported that administration of anti-inflammatory agents such as celecoxib and botulinum toxin type A attenuates joint contracture and intra-articular adhesion as well as fibroblast proliferation (Baranowski et al. 2019, Gao et al. 2017, Li et al. 2013a). Fibroblasts produce extracellular matrix proteins such as collagens, and thus fibroblast proliferation is an important process in the development of joint fibrosis (Emami et al. 2012, Li et al. 2014). We therefore suggest that proliferation of fibroblasts triggered by inflammation plays an important role in forming joint capsule fibrosis and that inhibition of fibrosis may be essential for blocking the progression of arthrogenic contracture.

To inhibit fibroblast proliferation, we focused on the cell cycle inhibitor mitomycin C (MMC). In a clinical context, MMC is generally used as an anti-cancer drug (Kahmann et al. 2010). However, it also finds application pre-clinically and clinically as an anti-fibrotic drug for keloid, capsular contracture, and scarring after ocular surgery (Lan et al. 2003, Li et al. 2013b, Nava et al. 2017, Sidle and Kim 2011, Simman et al. 2003, Wang et al. 2012). MMC can attenuate the development of fibrosis as well as inhibit fibroblast proliferation in injury-induced intra-articular adhesion models (Kocaoglu et al. 2011, Li et al. 2013b, Wang et al. 2012).

Therefore, we hypothesized that remobilization-induced joint capsule fibrosis and progression of arthrogenic contracture would also be attenuated by MMC administration via inhibition of fibroblast proliferation. To test this hypothesis, we investigated the effects of MMC on joint ROM and histopathology in the remobilized rat knee.

Materials and Methods

Experimental animals

Twenty-five eight-week-old male Wistar rats (190-220 g; Japan SLC, Shizuoka, Japan) were used in this study. The rats were randomly divided into four groups: control (n=4), immobilization (IM: n=7), remobilization with saline injections after immobilization (RM: n=7), and remobilization with MMC injections
after immobilization (RM+M: n=7). In the control group, data from the right and left knees were treated as individual samples; therefore, we used data of eight knees from four rats as controls. Rats were housed in standard cages in a temperature-controlled room (20-25 °C) with 12 h light/dark cycles. Standard rodent chow and water were provided ad libitum. This experimental design was approved by the committee on animal experimentation of Hiroshima International University.

**Joint immobilization and remobilization**

The right knees of rats in the IM, RM, and RM+M groups were immobilized with an external fixator according to the method described in previous studies (Nagai et al. 2014, Ozawa et al. 2016). In brief, after anesthesia by intraperitoneal injection of sodium pentobarbital (32.4 mg/kg of body weight), Kirschner wires (01-132-50; MIZUHO, Tokyo, Japan) were screwed into the femur and the tibia and were fixed by wire and resin (Provinice Fast; Matsukaze, Kyoto, Japan) to immobilize knee joints at a flexion of approximately 140° (Fig. 1). During immobilization, rats could move freely using their four limbs. Knees in the control group were untreated. After three weeks, the fixation device was removed and rats in the RM and RM+M groups were allowed to recover for one week (remobilization). It is known that one week of remobilization following three weeks of immobilization induces fibrotic reactions in the joint capsule and arthrogenic contracture progression (Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2019). Rats in the IM group were analyzed immediately after removal of the fixator and represented data from immobilization without remobilization. It is known that one week of remobilization following three weeks of immobilization induces fibrotic reactions in the joint capsule and arthrogenic contracture progression (Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2019). Rats in the IM group were analyzed immediately after removal of the fixator and represented data from immobilization without remobilization. Therefore, data in the control and IM groups were collected at three weeks after starting the experiment, while data in the RM and RM+M groups were collected at four weeks.

**MMC treatment**

To inhibit remobilization-induced fibroblast proliferation, rats in the RM+M group received intra-articular injections of 0.08 mg of MMC (concentration 0.8 mg/ml). Because cell proliferation is active until three days after fixator removal (Kaneguchi et al. 2017), injections were given immediately after and three days after removal. The quantity of MMC administered was determined based on the literature to achieve an anti-proliferative effect (Kocaoglu et al. 2011). In the RM group, rats received intra-articular injections of the same volume of saline (0.1 ml) at the same time. Thus, rats in the RM and RM+M groups received two injections.

**ROM measurements**

At the end of experimental periods, we measured ROMs according to the method of our previous study (Kaneguchi et al. 2015). In brief, rats were anesthetized with intraperitoneal injection of sodium pentobarbital (32.4 mg/kg of body weight). After rat hindlimbs were skinned, rats were placed in the neutral spine position and the femur was manually fixed at 90° of the hip flexion, followed by 14.6 N mm of knee extension moment. This moment stretched the knee joint close to its physiological limit (Moriyama et al. 2006), but did not disrupt the knee soft tissues (Trudel and Uhthoff 2000). Using a 3D motion analysis system (Kinema Tracer; Kissei Comtec, Nagano, Japan), the angle between the femur and the fibula was measured as ROM before myotomy. Then, rats were sacrificed by exsanguination under sodium pentobarbital anesthesia, and knee flexor muscles were completely transected to remove the myogenic factor. Finally, ROM after myotomy was measured to evaluate arthrogenic contracture.

**Histological assessment**

**Tissue preparation**

After ROM measurements, the knee joints were harvested and immersion-fixed at flexion 90° in 0.1 M phosphate-buffered 4 % paraformaldehyde (pH 7.4) for 48 h at 4 °C. After fixation, samples were decalcified by 17.7 % ethylenediaminetetraacetic acid (pH 7.2, Osteosoft;
Merck Millipore, Darmstadt, Germany) and embedded in paraffin. Using a microtome, samples were cut into 4 μm sagittal sections at the medial mid condylar level.

**Cell counting**

Counting of cells was performed according to the methods described in previous studies (Kaneguchi et al. 2017, Kaneguchi et al. 2018a). In brief, sections were stained with hematoxylin and eosin. We photographed the superior, central, and inferior regions of the posterior joint capsule at 40× magnification and manually counted the number of cells. Cell numbers were then converted to cells per mm² of joint capsule.

**Counting of fibroblasts**

To visualize fibroblasts, we performed immunohistochemistry using anti-vimentin antibodies. Deparaffinized sections were treated with 1 % trypsin for 5 min at 37 °C for antigen retrieval. To quench endogenous peroxidase activity, sections were incubated with methanol containing 3 % H₂O₂ for 30 min. Nonspecific binding was blocked by 1 % normal horse serum in 0.01 M phosphate-buffered saline (PBS; pH 7.4) for 30 min. We then incubated sections with anti-vimentin antibody (1:1000 dilution; ab92547, Abcam, Cambridge, UK) for three hours at room temperature followed by rinsing with PBS. Secondary antibody (horse biotinylated anti-mouse/rabbit IgG, 1:250 dilution; BA-1400, Vector Laboratories, Burlington, CA, USA) was added for 30 min. After rinsing with PBS, we incubated sections with a streptavidin-biotin complex (1:50 dilution; Elite ABC, Vector Laboratories) for 30 min. Finally, immunoreactivity was visualized with a Dako EnVision + kit/HRP (DAB) (Dako Japan, Tokyo, Japan), followed by counterstaining with hematoxylin. While vimentin is often used as a fibroblast marker (Abdul et al. 2015, Glazebrook et al. 2008, Krejci et al. 2015, Wang et al. 2014), it is also expressed in other cell types, including endothelial cells, macrophages, neutrophils, and lymphocytes (Evans 1998). Therefore, spindle-shaped vimentin-positive cells not detected in luminal structures were considered fibroblasts (Kaneguchi et al. 2018a). Counting of fibroblasts was performed in the same way as cell counting.

**Calculating joint capsule collagen density**

We calculated collagen density following methods described previously (Kaneguchi et al. 2017). In brief, sections were stained with aldehyde fuchsin-Masson Goldner (AFMG) to identify collagen. We captured the posterior joint capsule just behind the meniscus at 20× magnification (Fig. 2A, B) and analyzed the digitized image using ImageJ software (National Institutes of Health, Bethesda, MD, USA). To isolate collagen, we extracted green color from the original color image using the Split Channels function. Using the Threshold function, an arbitrary threshold was set to determine the green stained area. Collagen density was calculated by dividing this area by the total joint capsule area.

**Measurement of joint capsule thickness**

Using AFMG-stained sections, the thickness of the posterior joint capsule was measured according to the
methods described previously (Kaneguchi et al. 2017). In brief, after the posterior region of the knee joint was photographed at 2× magnification, the distance between the posterior borders of the meniscus and the joint capsule was measured as joint capsule thickness using ImageJ software (Fig. 2A, B). All analyses were performed in an unblinded manner.

Statistical analysis

We performed statistical analyses using Dr. SPSS II for Windows (SPSS Japan Inc., Tokyo, Japan) and G*Power 3.1 (University of Düsseldorf, Düsseldorf, Germany). Normality of the distribution and homogeneity of variance were tested using the Kolmogorov-Smirnov and Levene tests, respectively. All data met normality and homoscedasticity assumptions. Therefore, one-way analysis of variance (ANOVA) and the Tukey’s post hoc test were applied. For all tests, a P-value of <0.05 was considered statistically significant. A post hoc power analysis was performed using G*Power 3.1.

Results

ROM

Knee extension ROMs before myotomy were 149±4°, 91±4°, 108±4°, and 107±5° in the control, IM, RM, and RM+M groups, respectively (Fig. 3A). Compared with the control group, ROMs were significantly reduced in all joint-immobilized groups (P<0.001). Among immobilized groups, ROMs in the RM and RM+M groups were significantly larger than that in the IM group (P<0.001). Between the RM and RM+M groups, there was no difference in ROM before myotomy (P=0.952). The statistical power for ROM before myotomy was 1.00.

Knee extension ROMs after myotomy, which can indicate restriction of ROM caused by arthrogenic factor, were 161±4°, 139±8°, 128±8°, and 138±5° in the control, IM, RM, and RM+M groups, respectively (Fig. 3B). In all joint-immobilized groups, ROMs were significantly reduced compared with the control group (P<0.001). Among immobilized groups, ROM in the RM group was significantly lower than in the IM group (P=0.019). However, ROM in the RM+M group did not differ from the IM group (P=0.977), but was significantly larger than in the RM group (P=0.048). The statistical power for ROM after myotomy was 1.00.

Cellularity

In the posterior joint capsule of the control (Fig. 4A) and IM (Fig. 4B) groups, we mainly observed spindle-shaped fibroblast-like cells and vascular endothelial cells, concluding there was no difference in cell number between these two groups (P=0.998, 3,985±867 and 4,084±569 cells/mm², respectively, Fig. 4E). Compared with the control and IM groups, we observed a greater cell number mainly due to proliferated spindle-shaped fibroblast-like cells in the RM group.
In the RM+M group (Fig. 4D), cell number was significantly smaller than in the RM group (P=0.001, 4,833±1,044 cells/mm², 66 % of RM group), but not significantly different from the control and IM groups (P=0.468 and 0.570, respectively, 121 % of the control group). The statistical power for cell number was 0.95.

The number of vimentin-positive fibroblasts also did not differ between the control (Fig. 5A) and IM (Fig. 5B) groups (P=1.000, 2,199±491 and 2,180±393 cells/mm², respectively, Fig. 5E). Vimentin-positive fibroblast number in the RM group (Fig. 5C) was significantly higher than those in the control and IM groups (P=0.001, 4,434±660 cells/mm², 202 % of the control group). Also, in the RM+M group (Fig. 5D), vimentin-positive fibroblast number was significantly higher than those in the control and IM groups (P=0.014 and 0.012, respectively, 3,149±556 cells/mm², 143 % of the control group). However, the number of vimentin-positive fibroblasts was significantly smaller in the RM+M group than in the RM group (P=0.001, 71 % of RM group). The statistical power for fibroblast number was 1.00.

**Collagen density**

In the control (Fig. 6A) and IM (Fig. 6B) groups, collagen fiber bundles in the posterior joint capsule were arranged with gaps. Collagen density was 54±4 % and 48±8 %, respectively. There was no significant difference
in collagen density between the control and IM groups (P=0.324, Fig. 6E). In the RM group (Fig. 6C), the gap of collagen fiber bundles disappeared and collagen density increased to 76±4 %, significantly different to the control and IM groups (P<0.001). In the RM+M group (Fig. 6D), gaps between collagen fiber bundles were partially restored and collagen density was 63±8 %. Collagen density in the RM+M group was significantly lower than that in the RM group (P=0.006), but significantly higher than in the control and IM groups (P=0.043 and 0.001, respectively). The statistical power for collagen density was 1.00.

**Joint capsule thickness**

In the control group (Fig. 7A), joint capsule thickness was 0.35±0.06 mm (Fig. 7E). In the IM group (Fig. 7B), the posterior joint capsule was slightly thickened (0.45±0.07 mm), but not significantly, compared with that in the control group (P=0.077). Joint capsule thickness in the RM group was 0.57±0.09 mm (Fig. 7C) and was significantly thicker than those in the control and IM groups (P<0.001 and P=0.014, respectively). In the RM+M group (Fig. 7D), joint capsule thickness tended to be lower than in the RM groups (0.47±0.07 mm, P=0.067) and was
such as collagen, are produced by fibroblasts. In joint arthropathic contracture. Extracellular matrix proteins, following remobilization together with progressing thickness and collagen density in the joint capsule

2013a). Furthermore, we observed increased joint capsule which may be due to intra-articular (micro) injury could prevent further decrease in ROM after myotomy, Our results indicate that MMC has beneficial effects on arthrogenic contracture but not myogenic one.

Three weeks of immobilization significantly reduced ROMs both before and after myotomy. After one week of remobilization, ROM before myotomy increased but after myotomy further decreased. These results indicate that remobilization improves myogenic contracture, but aggravates arthrogenic contracture oppositely. Although immobilization-induced arthrogenic contracture is not improved by remobilization (Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2018b, Kaneguchi et al. 2019, Trudel et al. 2014), arthrogenic contracture in intra-articular adhesion model using joint immobilization with intra-articular injury partially recovers after remobilization (Baranowski et al. 2018). These findings suggest that arthrogenic contracture attributed to intra-articular injury may be variable in contrast with immobilization only. Intra-articular injections of MMC during remobilization could prevent further decrease in ROM after myotomy, which may be due to intra-articular (micro) injury (Kaneguchi et al. 2017). However, MMC injections did not improve ROM before myotomy. Our results indicate that MMC has beneficial effects on arthrogenic contracture but not on myogenic one.

Fibrosis in joint components strongly contributes to progressing arthrogenic contracture in remobilized (Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2018b) as well as injured joints (Fukui et al. 2000, Fukui et al. 2001, Gao et al. 2017, Li et al. 2013a). Further, we observed increased joint capsule thickness and collagen density in the joint capsule following remobilization together with progressing arthrogenic contracture. Extracellular matrix proteins, such as collagen, are produced by fibroblasts. In joint injury-induced contracture, inhibiting fibroblast proliferation by anti-proliferative agents MMC or hydroxycamptothecin can attenuate fibrosis in intra-articular adhesion sites (Li et al. 2013b, Liang et al. 2014). Therefore, it seems likely that fibroblast proliferation plays an important role in generating joint fibrosis. In our present and previous studies, we observed development of joint capsule fibrosis together with fibroblast proliferation during remobilization (Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2018b, Kaneguchi et al. 2019), suggesting that fibroblast proliferation contributes to fibrosis formation in remobilized joints. We previously revealed that administering the steroidal anti-inflammatory drug dexamethasone during remobilization can prevent joint capsule fibrosis by suppressing hypercellularity with increasing fibroblast numbers (Kaneguchi et al. 2018b).

In the present study, administering MMC, which selectively prevents cell proliferation without inhibiting inflammation, was also able to attenuate joint capsule fibrosis; this prevented arthrogenic contracture progression during remobilization. We previously reported that inflammatory reactions reach their peak within one day of remobilization, but that arthrogenic contracture progression is not observed at that point (Kaneguchi et al. 2017). Progression of arthrogenic contracture characterized by development of joint capsule fibrosis is observed only after inflammation (Kaneguchi et al. 2017). These findings suggest that fibroblast proliferation (and subsequent upregulation of collagens) triggered by inflammation plays an important role in driving fibrotic processes, which induces arthrogenic contracture progression in remobilized joints.

In immobilized joints, remobilization can improve myogenic (Kaneguchi et al. 2017, Trudel et al. 2014) but not arthrogenic contracture (Kaneguchi and Ozawa 2017, Kaneguchi et al. 2017, Kaneguchi et al. 2018a, Kaneguchi et al. 2018b, Kaneguchi et al. 2019, Trudel et al. 2014). Therefore, effective therapeutic interventions for arthrogenic contracture are needed to avoid permanent joint contracture. Some animal and clinical studies reported the effectiveness of anti-inflammatory and anti-fibrotic agents on the attenuation of joint contracture (Baranowski et al. 2019, Usher et al. 2019). In the clinical setting, however, treatment options for joint contracture are limited to passive joint movements such as stretching, manipulation under anaesthesia (MUA), or surgical treatments (Charalambous and Morrey 2012, Wong et al. 2015).
Previous studies identify no positive effects of stretching on joint contracture (Harvey et al. 2017a, Harvey et al. 2017b, Moseley et al. 2005). MUA and surgical treatments are effective to improve joint contracture, but have the risk of complications, including nerve symptoms, heterotopic ossification, and instability (Cai et al. 2015, Usher et al. 2019). Developing new therapeutic strategies as alternatives to current treatments is therefore a critical concern (Wong et al. 2015). In this study, we demonstrated that intra-articular injections of the cell cycle inhibitor MMC effectively attenuates remobilization-induced joint capsule fibrosis and arthrogenic contracture progression. Inhibiting fibroblast proliferation during remobilization may become a novel therapeutic strategy in treating immobilization-induced arthrogenic contracture.

This study has some limitations. First, all analyses were performed in an unblinded manner. We thus cannot exclude the possibility of the subjective bias. Second, we immobilized knee joint using external fixator constructed by Kirschner wires, wire, and resin. Cast immobilization might be more suitable to mimic the human situation after the orthopedic disorders. Third, immunohistochemistry was performed only for the fibroblast. Both fibroblasts and myofibroblasts are major contributors to fibrotic changes (Hinz et al. 2012, Kendall and Feghali-Bostwick 2014). In particular, myofibroblasts expressing α-smooth muscle actin (α-SMA) have high extracellular matrix protein production capacity (Hinz et al. 2012, Kendall and Feghali-Bostwick 2014) and thus play a central role in joint fibrosis (Baranowski et al. 2019, Li et al. 2013b). Identification of myofibroblasts by α-SMA would give valuable information.

In conclusion, the present study demonstrated that inhibiting fibroblast proliferation by intra-articular MMC injections during remobilization can benefit the treatment of arthrogenic contracture by attenuating joint capsule fibrosis.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

This study was supported by a grant from the Japanese Physical Therapy Association.

References


GAO ZY, WU JX, LIU WB, SUN JK: Reduction of adhesion formation after knee surgery in a rat model by botulinum toxin A. Biosci Rep 37, 2017. https://doi.org/10.1042/BSR20160460


